Tanvir Chodri, MD
Pulmonary Disease · Asheboro, NCNPI 1952399784
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $65,325 of the $80,439 with a category attached, or 81.2%. GSK accounts for 85.4% of it on its own, with 50 other manufacturers making up the rest. Reporting peaked in 2021 at $25,262 and has fallen 81.5% since, to $4,686 in 2025. Among pulmonary disease clinicians in NC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 649 payments — averaging $123.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$69K
- AstraZeneca$2K
- Medical Device Business Services, Inc.$2K
- Jazz Pharmaceuticals Inc.$809
- Boehringer Ingelheim$750
- Takeda Pharmaceuticals U.S.A., Inc.$649
- plus $6K from 45 others
What the payments were for
- Speaking & faculty fees$65,32581%
- Travel & lodging$1,7882%
- Food & beverage$12,90716%
- Education$4191%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRELEGY ELLIPTA$47,368
- MONARCH$1,536
- ANORO$244
- NUCALA$220
- AVYCAZ$125
- HYQVIA$120
- FASENRA$114
- CHARTIS CATHETER$108
- ZEPHYR DELIVERY CATHETER$108
- ZEPHYR ENDOBRONCHIAL VALVE$108
- PULMONX CHARTIS TABLET CONSOLE$108
- SUNOSI$107
How this compares
$80,439 in reported general payments places this provider in the 90th percentile of 393 pulmonary disease providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 49 | $683,557 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 919 | $675,951 |
| UptraviSelexipag | 31 | $609,091 |
| HizentraImmun Glob G(Igg)/Pro/Iga 0-50 | 34 | $299,366 |
| Tyvaso DpiTreprostinil | 13 | $292,512 |
| OpsumitMacitentan | 20 | $270,709 |
| Breo ElliptaFluticasone/Vilanterol | 223 | $106,563 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 135 | $99,909 |
| HyqviaIgg/Hyaluronidase,recombinant | 12 | $85,750 |
| XolairOmalizumab | 22 | $74,268 |
| FasenraBenralizumab | 11 | $65,120 |
| Pirfenidone | 59 | $50,216 |
| SymbicortBudesonide/Formoterol Fumarate | 148 | $38,774 |
| Spiriva RespimatTiotropium Bromide | 54 | $35,822 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 651 | $14,995 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Uptravi, Opsumit | $537 | $879,80051 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $68,677 | $788,2391,157 claims |
| Boehringer IngelheimOfev, Spiriva Respimat | $750 | $719,379103 claims |
| CSL BehringHizentra | $228 | $299,36634 claims |
| AstraZenecaBreztri Aerosphere, Fasenra, Symbicort | $1,564 | $203,804294 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Hyqvia | $649 | $85,75012 claims |
| PfizerEliquis | $25 | $14,61223 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 393 pulmonary disease providers in North Carolina.
Other pulmonary disease in Asheboro
- Michael PritchettPinehurst$1.3M
- Michael WertGreensboro$412K
- Eugene BleeckerWinston Salem$357K
- Bradley IcardPinehurst$299K
- James DonohueChapel Hill$271K
- Eric MeltzerDurham$262K
- Daniel BreaultWilmington$257K
- Scott SkiboPinehurst$229K
- Jill OharWinston Salem$226K
- Priyank DesaiRocky Mount$199K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.